Company Profile
Arcturus Therapeutics Holdings Inc. Stock Price, News & Analysis
- Ticker:
- ARCT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.08 USD (-2.88%)
Close
Last updated: August 6, 2026
217M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ARCT closed down 2.88% at $6.08. No new same-company headline was identified in the current news window.
Company overview
Business overview
Arcturus Therapeutics is an RNA medicines company focused on mRNA and self-amplifying RNA technologies. Its story is built around platform science that aims to produce vaccines and therapeutics across multiple disease areas.
Geographic Base and Sector Classification
Arcturus is headquartered in the United States and listed on NASDAQ. It sits in platform biotechnology with a strong RNA-technology identity.
Business Model Characteristics
The company depends on platform validation, clinical progress, and the ability to convert RNA science into durable product revenue. Investors watch vaccine or therapeutic data, partnerships, and manufacturing capability.
Position Within the Biotechnology Landscape
Arcturus occupies a platform-RNA niche within biotech. It is sensitive to whether self-amplifying RNA can create differentiated therapeutic value beyond the first wave of products.
Future catalysts
Arcturus’s catalysts are mRNA-platform updates, vaccine and therapeutic development, and any partnership or clinical step that keeps the platform credible. The company still needs human proof.
Recent news
- 01
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
Source: Arcturus Therapeutics Holdings Inc.
- 02
Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate
Source: Arcturus Therapeutics Holdings Inc.
- 03
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health
Source: Arcturus Therapeutics Holdings Inc.
- 04
Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study
Source: Arcturus Therapeutics Holdings Inc.
- 05
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
Source: Arcturus Therapeutics Holdings Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Arcturus Therapeutics Holdings Inc. (ARCT)?
Arcturus Therapeutics Holdings Inc. (ARCT) most recently closed at 6.08 USD, a -2.88% move versus the previous session.
What is the market cap of Arcturus Therapeutics Holdings Inc. (ARCT)?
Arcturus Therapeutics Holdings Inc. currently has a market capitalization of 217M USD on BioPharmSignal.
What does Arcturus Therapeutics Holdings Inc. do?
Arcturus Therapeutics is an RNA medicines company focused on mRNA and self-amplifying RNA technologies. Its story is built around platform science that aims to produce vaccines and therapeutics across multiple disease areas.
On which exchange is ARCT stock listed?
Arcturus Therapeutics Holdings Inc. (ARCT) is associated with NASDAQ, United States, Biopharma.
What is Arcturus?
Arcturus’s catalysts are mRNA-platform updates, vaccine and therapeutic development, and any partnership or clinical step that keeps the platform credible.
Which conditions is Arcturus Therapeutics Holdings Inc. targeting with Arcturus?
Arcturus’s catalysts are mRNA-platform updates, vaccine and therapeutic development, and any partnership or clinical step that keeps the platform credible.
How does Arcturus Therapeutics Holdings Inc. describe recent progress with Arcturus?
Arcturus’s catalysts are mRNA-platform updates, vaccine and therapeutic development, and any partnership or clinical step that keeps the platform credible.
What is Therapeutics?
Arcturus Therapeutics is an RNA medicines company focused on mRNA and self-amplifying RNA technologies.